Wortel C, van de Wetering R, Stork E, Kissel T, Reijm S, van der Woude D
Nat Commun. 2025; 16(1):1582.
PMID: 39939347
PMC: 11822119.
DOI: 10.1038/s41467-025-56786-x.
Fiore N, Willcox K, Dayani D, Zuberi Y, Heijnen C, Grace P
Brain Behav Immun. 2025; 125:371-387.
PMID: 39870199
PMC: 11903150.
DOI: 10.1016/j.bbi.2025.01.015.
Ou L, Setegne M, Elliot J, Shen F, Dassama L
Chem Rev. 2025; 125(4):2120-2183.
PMID: 39818743
PMC: 11870016.
DOI: 10.1021/acs.chemrev.4c00595.
Silvestri N
Muscle Nerve. 2025; 71(3):422-428.
PMID: 39744896
PMC: 11799394.
DOI: 10.1002/mus.28334.
Zakrzewicz A, Vanderheyden K, Galaly Y, Feldhoff S, Sips M, Brinkhaus M
Front Immunol. 2024; 15:1473637.
PMID: 39450168
PMC: 11499148.
DOI: 10.3389/fimmu.2024.1473637.
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants.
Jing S, Zhang Y, Lin Y, Gu X, Liu J, Guglietta A
Drugs R D. 2024; 24(4):505-515.
PMID: 39368043
PMC: 11652471.
DOI: 10.1007/s40268-024-00490-6.
Immunomodulatory and anti-inflammatory properties of immunoglobulin G antibodies.
Hematianlarki M, Nimmerjahn F
Immunol Rev. 2024; 328(1):372-386.
PMID: 39340138
PMC: 11659946.
DOI: 10.1111/imr.13404.
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions.
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E
Am J Hematol. 2024; 99(12):2351-2366.
PMID: 39324647
PMC: 11560617.
DOI: 10.1002/ajh.27487.
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
Howard Jr J, Vu T, Li G, Korobko D, Smilowski M, Liu L
Neurotherapeutics. 2024; 21(5):e00378.
PMID: 39227284
PMC: 11579873.
DOI: 10.1016/j.neurot.2024.e00378.
Nanobody-based heavy chain antibodies and chimeric antibodies.
Koch-Nolte F
Immunol Rev. 2024; 328(1):466-472.
PMID: 39212236
PMC: 11659929.
DOI: 10.1111/imr.13385.
Targeted Treatments for Myasthenia Gravis in Children and Adolescents.
Ramdas S, Painho T, Vanegas M, Famili D, Lim M, Jungbluth H
Paediatr Drugs. 2024; 26(6):719-740.
PMID: 39198371
DOI: 10.1007/s40272-024-00649-3.
Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.
Devanaboyina S, Li P, LaGory E, Poon-Andersen C, Cook K, Soto M
MAbs. 2024; 16(1):2383013.
PMID: 39051531
PMC: 11275528.
DOI: 10.1080/19420862.2024.2383013.
Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis.
Cavalcante P, Mantegazza R, Antozzi C
Front Immunol. 2024; 15:1404191.
PMID: 38903526
PMC: 11187261.
DOI: 10.3389/fimmu.2024.1404191.
Blood-based therapies to combat neurodegenerative diseases.
Lee J, Lim M, Koh R, Tsen M, Chye S
Metab Brain Dis. 2024; 39(5):985-1004.
PMID: 38842660
DOI: 10.1007/s11011-024-01368-x.
FcRn Inhibitor Therapies in Neurologic Diseases.
Alfaidi N, Karmastaji S, Matic A, Bril V
CNS Drugs. 2024; 38(6):425-441.
PMID: 38724842
DOI: 10.1007/s40263-024-01090-3.
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.
Ma G, Crowley A, Heyndrickx L, Rogiers I, Parthoens E, Van Santbergen J
JCI Insight. 2024; 9(10).
PMID: 38713534
PMC: 11141909.
DOI: 10.1172/jci.insight.176166.
IL-6-mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation.
Zhang P, Fleming P, Andoniou C, Waltner O, Bhise S, Martins J
J Clin Invest. 2024; 134(7).
PMID: 38557487
PMC: 10977988.
DOI: 10.1172/JCI174184.
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Howard Jr J, Bril V, Vu T, Karam C, Peric S, De Bleecker J
Front Neurol. 2024; 14:1284444.
PMID: 38318236
PMC: 10842202.
DOI: 10.3389/fneur.2023.1284444.
Impact of structural modifications of IgG antibodies on effector functions.
Damelang T, Brinkhaus M, van Osch T, Schuurman J, Labrijn A, Rispens T
Front Immunol. 2024; 14:1304365.
PMID: 38259472
PMC: 10800522.
DOI: 10.3389/fimmu.2023.1304365.
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells .
Qureshi O, Sutton E, Bithell R, West S, Cutler R, McCluskey G
MAbs. 2024; 16(1):2300155.
PMID: 38241085
PMC: 10802195.
DOI: 10.1080/19420862.2023.2300155.